1. News related to events and topics or subjects or issues:
The Trump administration announced funding of $1.6 million for a hepatitis B vaccination study in Guinea-Bissau, where nearly 20% of adults carry the virus. The trial will give or withhold the vaccine at birth to compare overall health outcomes. Experts have criticized the study as highly unethical, risky, and unnecessary, noting that the vaccine’s safety and effectiveness are already well established and widely recommended by the World Health Organization.
2. Causes of events and topics or subjects or issues:
The study follows a CDC policy change under US Health Secretary Robert F. Kennedy Jr., who promotes anti-vaccine views and has questioned standard immunizations. Guinea-Bissau, with fragile healthcare and high hepatitis B prevalence, was chosen instead of low-risk countries like Denmark or the US. Researchers with prior questionable findings will conduct the trial. Experts warn this reflects neocolonialist attitudes, risks misinterpreted results, and may worsen distrust in global public health initiatives.
3. Lessons to be learned from events and topics or subjects or issues:
The controversy highlights the importance of ethical standards, informed consent, and prioritizing proven public health interventions. Global vaccination programs must avoid politicization to protect vulnerable populations. Experts emphasize increasing coverage of birth-dose hepatitis B vaccines rather than experimental trials that withhold treatment. Transparent research, robust oversight, and evidence-based policies are essential to maintain trust in science, safeguard children’s health, and ensure international health aid supports proven, effective interventions rather than risky experiments
